Abstract:HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 29, No. 1Vascular Remodeling in Diabetes Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBVascular Remodeling in DiabetesDon’t Leave Without Your STAT5 Anna Zampetaki and Qingbo Xu Anna ZampetakiAnna Zampetaki From the Cardiovascular Division, King’s College London BHF Centre, London, UK. Search for more papers by this author and Qingbo XuQingbo Xu From the Cardiovascular Division, King’s College London BHF Centre, London, UK. Search for more papers by this author Originally published1 Jan 2009https://doi.org/10.1161/ATVBAHA.108.178137Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:10–11Diabetes mellitus is associated with increased risk of cardiovascular disease. A widespread endothelial dysfunction, altered production of vasoactive substances and superoxide and modification of the basement membranes, is believed to play a decisive role in the vascular complications observed in diabetes.1 More importantly perhaps, in diabetic patients collateral vessel development after vascular occlusion is impaired. It seems that in these patients, arteriogenesis, the growing of preexisting arteriolar connections into collateral to restore the blood supply to the ischemic area, is severely affected.2,3 This process of active vascular remodeling involves the recruitment of circulating monocytes-macrophage subsets that have a strong angiogenic response. Although these circulating angiogenic cells (CAC) do not adopt a typical endothelial phenotype in vitro, they are capable of enhancing neovascularization in a paracrine manner in vivo and are critical regulators of wound healing and tissue regeneration.4 Extensive studies have shown that the numbers of circulating angiogenic cells are significantly lower in type II diabetes, and their angiogenic potential is also dramatically diminished. These cells display defective adhesion to the endothelium, reduced proliferation rate, and impaired ability to create new vascular structures.5–7 Thus, to pursue any therapeutic application it is necessary to identify the signaling pathways and treatments that promote the proliferation and improve the functional capacity of circulating angiogenic cells in diabetes.See accompanying article on page 114In this issue of Atherosclerosis, Thrombosis, and Vascular Biology, Dentelli et al8 delineate the molecular mechanisms involved in interleukin (IL) 3–induced angiogenic cell expansion. Previous studies by the same group have revealed that this angiogenic mediator released by activated T cells can provide a permissive environment that enables angiogenic cells to expand and directly contribute to neovascularization.9 In their present work, they demonstrate that IL-3 induces the formation of a STAT5/PPARγ transcriptional complex that controls cyclin D1 expression and can partially rescue diabetic angiogenic cell bioavailability. The regulatory mechanism that they uncover is remarkable. On stimulation of CAC with IL-3, STAT5 transcription factors are activated. The phosphorylated STAT5s form homo- and heterodimeric complexes and translocate to the nucleus where they bind to specific DNA binding sites on PPARγ promoter and initiate transcription. This upregulation of PPARγ expression is a necessary step to promote entry into the cell cycle as knockdown of PPARγ expression ablates this response. Interestingly, activation of PPARγ signaling using specific endogenous ligands or synthetic agonists fails to mimic the response to IL-3, indicating that phosphorylation of STAT5 plays a pivotal role and acts as an upstream signal for activation of PPARγ in a ligand-independent manner. STAT5 and PPARγ will subsequently form a complex on the cyclin D1 promoter and induce cyclin D1 expression (Figure). Download figureDownload PowerPointFigure. A, IL-3 stimulates STAT5 transcription factors. The phosphorylated STAT5s translocate to the nucleus where they bind to specific DNA binding sites on PPARgamma promoter and initiate transcription. B, STAT5 and PPARgamma subsequently form a complex on the cyclin D1 promoter, inducing cyclin D1 expression and progression into the cell cycle.These findings are rather intriguing given the nature of the transcription factors that are involved. STAT5 is activated in response to various hematopoietic cytokines. The STAT5ab−/− knockout mice are characterized by fetal anemia and increased apoptosis of fetal liver erythroid progenitors. Surprisingly, peripheral hematology of the STAT5ab−/− mice is not dramatically altered, although reductions in the numbers of IL-3 and GM-colony stimulating factor (CSF) responsive progenitors and IL-7 responsive B-lymphoid progenitors have been reported. Competitive repopulation assays demonstrated that bone marrow and fetal liver cells of STAT5ab−/− mice have a decreased repopulating activity in granulocyte, macrophage, erythroid, and B-lymphocytes populations, with no detectable engraftment of T lymphocytes, suggesting that STAT5 is required to sustain a hematopoietic reserve.10,11PPARγ on the other hand belongs to a family of nuclear receptors. After ligand binding, it heterodimerizes with the retinoid X receptor, binds to responsive DNA elements, and induces gene expression. Several reports have implicated PPARγ in the control of cell cycle, apoptosis, and biological events such as adipogenesis12 and bone homeostasis.13 In vitro studies using PPARγ agonists have suggested that it mediates the beneficial effects of statins14 and that its activation can increase the numbers and the functional capacity of circulating angiogenic cells from diabetic patients.15,16 In diabetes, PPARγ synthetic ligands such as thiazolidinedione drugs (TZD) are commonly used to improve insulin sensitivity and exert antiatherosclerotic and antiinflammatory effects.Interestingly, bidirectional crosstalk between STAT5 and PPAR signaling seems to control the response to growth hormone (GH). Both inhibition of PPARα transcriptional activity mediated by STAT5b and downregulation of STAT5b transcriptional activity by PPARα and PPARγ have been reported.17,18 The findings presented in this study further add to the complexity of STAT5 and PPAR partnership, as a novel direct physical interaction of the two factors in a transcriptional complex is demonstrated. The formation of this heterodimer seems to act as a switch, which either allows the expansion of circulating angiogenic cells or suspends it. As identifying ways of increasing the numbers of circulating angiogenic cells in diabetic patients is extremely important, it would be critical to define the other regulators that are involved in this interaction and that could potentially serve as targets for novel therapeutic interventions. Monitoring the effect of IL-3 treatment on other members of the PPAR family would also provide valuable insights into the biology of circulating angiogenic cells in diabetic patients. In conclusion, the present work brought forward a new concept that could stimulate further research and could lead to the design of novel more effective approaches capable of improving vascular function.Received October 18, 2008; revision accepted October 22, 2008. Sources of FundingThis work was supported by grants from the British Heart Foundation and Oak Foundation.DisclosuresNone.FootnotesCorrespondence to Professor Qingbo Xu, Cardiovascular Division, King’s College London, 125 Cold Harbour Lane, London SE5 9NU, UK. E-mail [email protected] References 1 Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet. 1997; 350 Suppl 1: SI9–SI13.CrossrefMedlineGoogle Scholar2 Schaper W, Buschmann I. Collateral circulation and diabetes. Circulation. 1999; 99: 2224–2226.CrossrefMedlineGoogle Scholar3 Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation. 2000; 102: 185–190.CrossrefMedlineGoogle Scholar4 Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008; 28: 1584–1595.LinkGoogle Scholar5 Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002; 106: 2781–2786.LinkGoogle Scholar6 Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg S, Tiengo A, Agostini C, Avogaro A. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006; 26: 2140–2146.LinkGoogle Scholar7 Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL, Kern TS, Grant MB. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007; 56: 960–967.CrossrefMedlineGoogle Scholar8 Dentelli P, Trombetta A, Togliatto G, Zeoli A, Rosso A, Uberti B, Orso F, Taverna D, Pegoraro L, Brizzi MF. Formation of STAT5/PPARγ transcriptional complex modulates angiogenic cell bioavailability in diabetes. Arterioscler Thromb Vasc Biol. 2009; 29: 114–120.LinkGoogle Scholar9 Zeoli A, Dentelli P, Rosso A, Togliatto G, Trombetta A, Damiano L, di Celle PF, Pegoraro L, Altruda F, Brizzi MF. Interleukin-3 promotes expansion of hemopoietic-derived CD45+ angiogenic cells and their arterial commitment via STAT5 activation. Blood. 2008; 112: 350–361.CrossrefMedlineGoogle Scholar10 Bunting KD, Bradley HL, Hawley TS, Moriggl R, Sorrentino BP, Ihle JN. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 2002; 99: 479–487.CrossrefMedlineGoogle Scholar11 Schuringa JJ, Wu K, Morrone G, Moore MA. Enforced activation of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem cells that contribute to hematopoiesis in vivo. Stem Cells. 2004; 22: 1191–1204.CrossrefMedlineGoogle Scholar12 Lehrke M, Lazar MA. The many faces of PPARgamma. Cell. 2005; 123: 993–999.CrossrefMedlineGoogle Scholar13 Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007; 13: 1496–1503.CrossrefMedlineGoogle Scholar14 Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa Y, Kawada T, Brownlee M, Nishikawa T, Araki E. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007; 100: 1442–1451.LinkGoogle Scholar15 Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 2005; 183: 163–167.CrossrefMedlineGoogle Scholar16 Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J. 2006; 152: 1051 e1051–e1058.Google Scholar17 Shipley JM, Waxman DJ. Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Mol Pharmacol. 2003; 64: 355–364.CrossrefMedlineGoogle Scholar18 Zhou YC, Waxman DJ. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b. J Biol Chem. 1999; 274: 2672–2681.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kim O and Song J (2020) The importance of BDNF and RAGE in diabetes-induced dementia, Pharmacological Research, 10.1016/j.phrs.2020.105083, 160, (105083), Online publication date: 1-Oct-2020. Beigneux A, Gin P, Davies B, Weinstein M, Bensadoun A, Fong L and Young S (2009) Highly Conserved Cysteines within the Ly6 Domain of GPIHBP1 Are Crucial for the Binding of Lipoprotein Lipase, Journal of Biological Chemistry, 10.1074/jbc.M109.046391, 284:44, (30240-30247), Online publication date: 1-Oct-2009. January 2009Vol 29, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/ATVBAHA.108.178137PMID: 19092137 Originally publishedJanuary 1, 2009 PDF download Advertisement

Abstract:Editorial FocusPhosphoinositide 3-kinase therapy in diabetic cardiomyopathy: unravelling an enigmaYaguang Bi, Yingmei Zhang, and Jun RenYaguang BiDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, ChinaCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, Wyoming, Yingmei ZhangDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China, and Jun RenDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, ChinaCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WyomingPublished Online:08 Apr 2020https://doi.org/10.1152/ajpheart.00160.2020This is the final version - click for previous versionMoreSectionsPDF (272 KB)Download PDFDownload PDFPlus ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmail Diabetes mellitus, the most prevalent noncommunicable epidemic threat, is expected to reach an astonishing 600 million by year 2035 (1). Cardiovascular anomalies are commonly seen in diabetes, contributing to the high morbidity and mortality in patients with diabetes (5, 9, 11). In particular, undesired geometric and functional changes develop in diabetic hearts, independent of any macro- and microvascular comorbidities, leading to pronounced cardiac remodeling, systolic and diastolic dysfunction, including compromised myocardial contractile capacity, and prolonged duration and reduced velocity of contraction and relaxation, a condition commonly known as diabetic cardiomyopathy, first described by Rubler and colleagues in 1972 (5, 9, 11). Clinical observations using electrocardiogram and echocardiography have unveiled substantial changes in diabetic human hearts including altered left ventricular ejection time, preejection duration, left ventricular filling time, action potential duration, ventricular wall stiffness, and ejection fraction (5, 9, 11). Ample cellular and molecular mechanisms have been postulated for the pathogenesis of diabetic cardiomyopathy, encompassing mitochondrial injury, oxidative stress, inflammation, apoptosis, autophagy failure, disturbed energy metabolism, and intracellular Ca2+ defect (5, 9). Preclinical evidence over the past decades has also indicated a cadre of cell signaling therapeutic targets and strategies, such as antioxidative [nuclear factor erythroid 2-like 2 (Nrf2) activators, curcumin products, vitamins, and metallothionein derivatives], antifibrotic (melatonin, resveratrol, relaxin, and phosphodiesterase 5 inhibitors), anti-inflammatory [luteolin, Klotho, ursolic acid, epigallocatechin-3-gallate, statins, Toll-like receptor 4 (TLR4) inhibitors, NOD-like receptor family pyrin domain containing 3 (NLRP3) inhibitors, and tumor necrosis factor-α (TNF-α) inhibitors] and antiapoptotic (Fisetin, hydrogen sulfide, and lipid lowering statins) agents (5, 9, 11). Many of these interventions involve multiple therapeutic benefits such as concurrent antioxidation and anti-inflammation. Nonetheless, subsequent clinical trials for these therapeutic maneuvers, although somewhat promising for initial results (9), remain to be fully validated. Much more work is still warranted to better understand the pathogenesis of such myopathic condition in patients with diabetes and in particular type 2 diabetes (T2D), which is much more prevalent in comparison with type 1 diabetic (T1D) populations.In a recent issue of the American Journal of Physiology-Heart and Circulatory Physiology, Prakoso and colleagues (8) reported that administration of recombinant adeno-associated viral vectors carrying a constitutively active phosphoinositide 3-kinase [PI3K (p110α)] construct (rAAV6-caPI3K) effectively ameliorated diabetic cardiac remodeling and contractile dysfunction in a T2D model using a combination of high-fat diet (42% energy intake from fat) and streptozotocin (3 consecutive 55 mg/kg body wt ip). These authors noted evident cardiac anomalies in this preclinical T2D model as manifested by impaired left ventricular systolic function (fractional shortening and velocity of circumferential fiber shortening) and unfavorable cardiac remodeling (hypertrophy and interstitial and perivascular collagen deposition). Strikingly, T2D-induced cardiac dysfunction and remodeling were effectively rescued by a single delivery of cardiac targeted rAAV6-caPI3K. Mechanistically, these authors revealed decreased levels of reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress in response to the cardiac-selective rAAV6-caPI3K delivery (Fig. 1), which seems to underscore functional and geometric benefits from PI3K (p110α) gene therapy (8). Earlier finding from this group reported that the very same cardiac rAAV6-caPI3K (p110α) gene delivery greatly limits cardiac remodeling, contractile dysfunction, ER stress, and apoptosis in streptozotocin (5 consecutive 55 mg/kg body wt ip)-induced T1D model, possibly through regulation of NADPH oxidase (7). It is noteworthy that rAAV6-caPI3K was delivered following the establishment of diabetic cardiomyopathy phenotype in both T2D and T1D models (7, 8), mimicking a clinically relevant situation. These findings collectively denote an important role for PI3K in the novel therapeutics against diabetic cardiomyopathy.Fig. 1.Schematic diagram depicting possible mechanism(s) of involved in phosphoinositide 3-kinase (PI3K)α-induced beneficial effects against diabetes-induced anomalies in cardiac contractile function, morphology, and cell survival. PI3Kα (p110α) inhibits endoplasmic reticulum (ER) stress and oxidative stress to counteract diabetic insult to the heart. rAAV6-caPI3K, recombinant adeno-associated viral vectors carrying a constitutively active PI3K (p110α) construct; ROS, reactive oxygen species.Download figureDownload PowerPointPI3Ks belong to a large family of heterodimer lipid/protein kinases that serve as a central regulator for both physiological and pathophysiological processes, including cell growth and cell survival (2, 6). PI3Ks (class I) comprise a catalytic subunit (p110α, p110β, or p110δ), which is bound to the regulatory subunits (p85 and p55). Ample findings have depicted a rather important role for the p110α subunit along with its downstream signaling molecule Akt in the regulation of insulin signaling and metabolic profiles in particular in the etiology of insulin resistance, obesity, and diabetes mellitus (2–4, 6). PI3Kα ablation is embryonically lethal, whereas adipose PI3K (p110α) deletion results in overt adiposity and body weight gain (2). Likewise, the kinase-dead knock-in allele of p110α of PI3K displays hyperinsulinemia and impaired glucose tolerance, a phenotype reminiscent of those seen with deficiency in p85 regulatory subunit of PI3K. Mice with diminished cardiac PI3K (p110α) activity elicited by a dominant negative (dn) PI3K (p110α) mutant or deletion of p85 subunits exhibited cardiac atrophy at basal condition and dampened hypertrophic response upon exercise. To the contrary, transgenic mice with a constitutively active PI3K (p110α) mutant exhibited physiological cardiac hypertrophy under basal conditions and improved cardiac function or lifespan in stress conditions such as myocardial infarction or dilated cardiomyopathy (10). With genetically engineered mouse models, both beneficial and detrimental roles for PI3Kα have been noted in cardiovascular pathophysiological processes (2). In this context, governance of PI3K signaling, in particular p110α, is cardinal to the regulation of systemic glucose and lipid metabolism. However, limited availability of PI3K activators along with pharmacokinetic shortfalls such as poor bioavailability and fast metabolism, chemical instability, and safety/toxicity concerns have largely limited the clinical application of PI3K activators. Moreover, overstimulation of PI3K and its downstream signaling molecule Akt has been demonstrated to trigger cardiac hypertrophy and is deemed detrimental in certain conditions such as aging (4). To this end, the hunt for more specific or tissue-selective PI3K modulators may represent a novel approach in pharmacotherapy for the management of diabetes and diabetic complications. Although this study from Prakoso and colleagues (8) has unveiled the therapeutic potential of PI3K activation in the treatment and management of diabetic cardiomyopathy, more questions remain to be answered. First, can PI3K analog be employed for dyslipidemia and obesity-induced cardiovascular anomalies, and if so, what is the mechanism(s) of action behind PI3K (p110α)-elicited benefit against obesity-induced cardiovascular dysfunction? Given the well-established role of PI3K in insulin signaling and lipid metabolism (2) and close association between obesity and T2D (11), possible added benefit (or risk) of PI3K-targeted therapy in obese T2D should be weighed. Second, it was reported that loss of PI3Kα using genetically engineered mice failed to reveal any inherently pathological changes to the heart in otherwise healthy mice (6), somewhat inconsistent with those reported in mice overexpressing a dnPI3K (p110α) mutant or with deletion of p85 subunits (10). Thus, the onset and development of diabetic cardiomyopathy is unlikely originated from defects in PI3Kα itself. What is the precise role of PI3Kα in the pathogenesis of diabetic cardiomyopathy? Are there any other confounding factors to launch the “diabetic cardiomyopathy missile” in the presence of PI3K abnormality? At this time, proper clinical management for diabetic cardiomyopathy mainly encompasses proper control of glucose and lipid metabolism, correction of coronary artery diseases, hypertension and inflammation, along with nonpharmacotherapies such as lifestyle modification and exercise. Many of these measures should help to harness the PI3K signaling (such as exercise training), although the precise mechanism(s) of action remains elusive. Last but not the least, improper or chronic activation of PI3K-Akt signaling cascade may bring significant clinical concerns such as cancer prevalence, thus pharmacological therapies targeting PI3K may have to be handled with special caution under certain clinical scenarios.GRANTSThis work was supported in part by National Science Foundation Grant NSF-81770261.DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSY.B., Y.Z., and J.R. drafted, edited, and revised manuscript.REFERENCES1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137–149, 2014. doi:10.1016/j.diabres.2013.11.002. Crossref | PubMed | ISI | Google Scholar2. Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020 March 3. [Epub ahead of print.] 2020. doi:10.1038/s41574-020-0329-9. Crossref | PubMed | ISI | Google Scholar3. Hu N, Ren J, Zhang Y. Mitochondrial aldehyde dehydrogenase obliterates insulin resistance-induced cardiac dysfunction through deacetylation of PGC-1α. Oncotarget 7: 76398–76414, 2016. doi:10.18632/oncotarget.11977. Crossref | PubMed | Google Scholar4. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 106: 1173–1191, 2011. doi:10.1007/s00395-011-0222-8. Crossref | PubMed | ISI | Google Scholar5. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122: 624–638, 2018. doi:10.1161/CIRCRESAHA.117.311586. Crossref | PubMed | ISI | Google Scholar6. McLean BA, Zhabyeyev P, Patel VB, Basu R, Parajuli N, DesAulniers J, Murray AG, Kassiri Z, Vanhaesebroeck B, Oudit GY. PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovasc Res 105: 292–303, 2015. doi:10.1093/cvr/cvv016. Crossref | PubMed | ISI | Google Scholar7. Prakoso D, De Blasio MJ, Qin C, Rosli S, Kiriazis H, Qian H, Du XJ, Weeks KL, Gregorevic P, McMullen JR, Ritchie RH. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci (Lond) 131: 1345–1360, 2017. doi:10.1042/CS20170063. Crossref | PubMed | ISI | Google Scholar8. Prakoso D, De Blasio MJ, Tate M, Kiriazis H, Donner DG, Qian H, Nash D, Deo M, Weeks KL, Parry LJ, Gregorevic P, McMullen JR, Ritchie RH. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes. Am J Physiol Heart Circ Physiol 318: H840–H852, 2020. doi:10.1152/ajpheart.00632.2019. Link | ISI | Google Scholar9. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020 February 20. [Epub ahead of print.] doi:10.1038/s41569-020-0339-2. Crossref | PubMed | ISI | Google Scholar10. Weeks KL, Gao X, Du XJ, Boey EJ, Matsumoto A, Bernardo BC, Kiriazis H, Cemerlang N, Tan JW, Tham YK, Franke TF, Qian H, Bogoyevitch MA, Woodcock EA, Febbraio MA, Gregorevic P, McMullen JR. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 5: 523–534, 2012. doi:10.1161/CIRCHEARTFAILURE.112.966622. Crossref | PubMed | ISI | Google Scholar11. Zhang Y, Whaley-Connell AT, Sowers JR, Ren J. Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. Pharmacol Ther 191: 1–22, 2018. doi:10.1016/j.pharmthera.2018.06.004. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for correspondence: J. Ren, Univ. of Wyoming College of Health Sciences, 1000 E. University Ave., Dept. 3375, Laramie, WY 82071 (e-mail: [email protected]edu). Previous Back to Top Next FiguresReferencesRelatedInformationRelated articlesGene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes 24 Mar 2020American Journal of Physiology-Heart and Circulatory PhysiologyCited ByHyperglycemic memory in diabetic cardiomyopathy18 December 2021 | Frontiers of Medicine, Vol. 25Weighted Gene Co-Expression Network Analysis Identifies ANGPTL4 as a Key Regulator in Diabetic Cardiomyopathy via FAK/SIRT3/ROS Pathway in Cardiomyocyte20 September 2021 | Frontiers in Endocrinology, Vol. 12Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy22 July 2021 | Frontiers in Endocrinology, Vol. 12Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathyBiomedicine & Pharmacotherapy, Vol. 128Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway19 May 2020 | Frontiers in Physiology, Vol. 11 More from this issue > Volume 318Issue 5May 2020Pages H1029-H1031 Copyright & PermissionsCopyright © 2020 the American Physiological Societyhttps://doi.org/10.1152/ajpheart.00160.2020PubMed32167783History Received 9 March 2020 Accepted 11 March 2020 Published online 8 April 2020 Published in print 1 May 2020 Metrics Downloaded 286 times

Vascular Remodeling in Diabetes

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Decreased Mobilization of Endothelial Progenitor Cells Contributes to Impaired Neovascularization in Diabetes

Type 1 Diabetes Impairs Vascular Relaxation Via Increases in Endothelial Glycolysis and Activation of the HIF1a-PFKFB3-Nox1 Pathway in Mice.

Novel Paracrine Action of Endothelium Enhances Glucose Uptake in Muscle and Fat

Novel Angiogenesis Role of GLP-1(32–36) to Rescue Diabetic Ischemic Lower Limbs via GLP-1R–Dependent Glycolysis in Mice

A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia

Reconstituted high-density lipoproteins rescue diabetes-impaired endothelial cell metabolic reprograming and angiogenic responses to hypoxia

Impairment in Endothelial Bioenergetics Contributes to Diabetes-Induced Vascular Dysfunction.

TGF-β1/ALK5-induced Monocyte Migration Involves PI3K and P38 Pathways and is Not Negatively Affected by Diabetes Mellitus

Diabetes impairs endothelial cell metabolic reprogramming and angiogenic responses to hypoxia, which are rescued by reconstituted high-density lipoproteins

Hyperglycemia-Suppressed SMARCA5 Disrupts Transcriptional Homeostasis to Facilitate Endothelial Dysfunction in Diabetes

High-glucose Induced HIF-1α Down-Regulation Impairs the Function of the Endothelial Progenitor Cells Via PI3K/AKT Signaling Pathway

Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes

Pgc-1 Alpha Is A Key Regulator Of Glucose-Induced Proliferation And Migration In Vascular Smooth Muscle Cells

Abstract WP327: Altered Bone Marrow Microenvironment Impacts Endothelial Precursor Cell Development and Egress in Mice With Type 2 Diabetes

882-P: A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R–Dependent Glycolysis

[Diabetes and peripheral arterial occlusive disease: therapeutic potential and pro-angiogenic strategies]

Phosphoinositide 3-Kinase Therapy in Diabetic Cardiomyopathy: Unravelling an Enigma

Diabetes Impaired Ischemia-Induced PDGF (Platelet-Derived Growth Factor) Signaling Actions and Vessel Formation Through the Activation of Scr Homology 2-Containing Phosphatase-1